Boehringer Mannheim
This article was originally published in The Gray Sheet
Executive Summary
David Giddings named president of Boehringer Mannheim Corporation and Staffan Ek appointed president of the diabetes care business. Giddings will continue in his position as chief operating officer and will now "assume responsibility for the corporate affairs" of the Corange division. Before arriving at BMC in 1992, Giddings served as vice president and general manager of Eastman Kodak's printing and publishing division and clinical diagnostics division. Ek most recently served as head of international sales and marketing for the diabetes care unit, joining the company in 1992 after 20 years at Pharmacia. Giddings and Ek replace Andre de Bruin, who served as both president and CEO of Boehringer and president of Diabetes Care. de Bruin resigned July 1 to "pursue new business opportunities in the health care field"
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.